Want to see GANX full AI Analyst Report?
Top Page
Gain Therapeutics
(NASDAQ:GANX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▲(5.26% Upside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance—minimal revenue alongside sizable, persistent losses and heavy cash burn—despite a relatively low-debt balance sheet. Technical indicators add moderate support with improving near-term momentum, while valuation is constrained by a negative P/E and lack of dividend yield.
Positive Factors
Low leverage and positive equity
Low debt and positive equity provide financial flexibility relative to many early-stage biotechs. This reduces immediate leverage risk and may help the company fund development without debt-service pressure, although continued losses could weaken this position.
Negative Factors
No meaningful revenue base
The absence of meaningful revenue confirms that the company remains dependent on external financing while its drug candidates are developed. Until a product is commercialized or partnered, operating performance will remain highly exposed to clinical and funding outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and positive equity
Low debt and positive equity provide financial flexibility relative to many early-stage biotechs. This reduces immediate leverage risk and may help the company fund development without debt-service pressure, although continued losses could weaken this position.
Read all positive factors
Gain Therapeutics (GANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$77.25M
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue GrowthN/A
EPS Growth23.02%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,643,620
10 Day Avg. Volume710,440
30 Day Avg. Volume1,073,672
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside278.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Gain Therapeutics Business Overview & Revenue Model
Company Description
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurologic...
Gain Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 55.18K | 140.11K | 164.99K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 55.18K | 140.11K | 164.99K |
| EBITDA | -19.10M | -19.21M | -19.79M | -22.10M | -17.43M | -13.87M |
| Net Income | -20.11M | -20.16M | -20.41M | -22.27M | -17.59M | -13.89M |
Balance Sheet | ||||||
| Total Assets | 15.42M | 22.82M | 12.12M | 18.61M | 24.10M | 38.99M |
| Cash, Cash Equivalents and Short-Term Investments | 13.08M | 20.84M | 10.39M | 16.79M | 20.14M | 36.88M |
| Total Debt | 609.87K | 732.07K | 653.01K | 1.03M | 1.27M | 1.61M |
| Total Liabilities | 4.13M | 4.25M | 4.78M | 6.03M | 5.22M | 4.17M |
| Stockholders Equity | 11.29M | 18.56M | 7.34M | 12.58M | 18.88M | 34.82M |
Cash Flow | ||||||
| Free Cash Flow | -18.95M | -18.47M | -18.90M | -18.88M | -14.81M | -12.46M |
| Operating Cash Flow | -18.95M | -18.47M | -18.87M | -18.87M | -14.69M | -12.37M |
| Investing Cash Flow | 0.00 | 0.00 | 4.98M | 10.22M | -14.77M | -94.21K |
| Financing Cash Flow | 25.35M | 28.45M | 13.01M | 12.64M | -78.77K | 41.77M |
Gain Therapeutics Technical Analysis
Negative
1.90
Price Trends
1.85
Negative
1.84
Negative
2.19
Negative
Market Momentum
0.01
Positive
42.20
Neutral
7.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Negative. The current price of 1.9 is below the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.85, and below the 200-day MA of 2.19, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 42.20 is Neutral, neither overbought nor oversold. The STOCH value of 7.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GANX.
Gain Therapeutics Risk Analysis
Gain Therapeutics disclosed 9 risk factors in its most recent earnings report. Gain Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gain Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $436.53M | -6.92 | -75.35% | ― | 220.34% | 55.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $77.25M | -3.54 | -161.58% | ― | ― | 23.02% | |
44 Neutral | $65.22M | -0.86 | -78.11% | ― | ― | 9.38% | |
41 Neutral | $22.12M | -2.81 | -92.03% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
GANX
Gain Therapeutics
1.77
-0.14
-7.33%
ABVC
ABVC BioPharma
0.83
-1.90
-69.60%
PMVP
PMV Pharmaceuticals
1.22
-0.27
-18.12%
PRLD
Prelude Therapeutics
5.47
4.34
384.07%
IMMX
Immix Biopharma
13.94
11.66
511.40%
Gain Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Gain Therapeutics Extends Cash Runway Into 2027 Operations
Positive
Jul 17, 2026
On July 16, 2026, Gain Therapeutics announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027, based on its current operating plans. This funding horizon encompasses the planned completion...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
Positive
Jun 29, 2026
On June 29, 2026, Gain Therapeutics said the U.S. Food and Drug Administration had cleared its Investigational New Drug application for GT-02287, enabling the launch of Phase 2 clinical development in Parkinson’s disease patients with or wit...
Executive/Board ChangesShareholder Meetings
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
Positive
Jun 25, 2026
On June 24, 2026, Gain Therapeutics, Inc. held its annual meeting of stockholders, where shareholders elected seven directors, including Gene Mack and Dov Goldstein, M.D., to serve one-year terms until their successors are duly chosen. The vote to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.